In 40 seconds
Lewy body dementia (DLB) and Parkinson's disease dementia (PDD) are the major Lewy-body spectrum dementias. There are effectively no published RCTs of rTMS or PEMF specifically in DLB. The Lefaucheur 2020 European guideline issues no recommendation. Three safety considerations make magnetic stimulation particularly risk-sensitive in DLB: visual-cortex hyperexcitability with documented seizure susceptibility, DBS overlap (some Parkinson's-spectrum patients have implanted deep brain stimulators which are an absolute contraindication to rTMS), and severe neuroleptic sensitivity that complicates the medication landscape. NICE NG97 applies — rTMS not recommended outside a trial. Consumer PEMF over the head has no DLB-specific human trial.
Quick facts
- rTMS evidence in DLB: Effectively none — no phase-3 RCT
- PEMF evidence in DLB: No human trial
- Lefaucheur 2020: No recommendation for DLB
- Critical contraindication: Implanted DBS (for Parkinson's-spectrum overlap) — absolute exclusion for rTMS
- Seizure risk: DLB may have higher baseline seizure susceptibility; some patients on cholinesterase inhibitors which lower threshold modestly
- Severe neuroleptic sensitivity: Antipsychotic use must be highly selective in DLB — affects rTMS protocol planning
- Standard care: Rivastigmine (NICE-recommended), donepezil, clonazepam for REM-sleep behaviour disorder, melatonin, falls prevention
Why DLB is treated with extra caution
DLB combines cognitive fluctuation, visual hallucinations, REM-sleep behaviour disorder and parkinsonism. The combination creates a unique safety landscape for any neuromodulation intervention.
Severe neuroleptic sensitivity
Up to 50% of people with DLB have a severe adverse reaction to first-generation and some second-generation antipsychotics — exacerbation of parkinsonism, sedation, autonomic instability, and an idiosyncratic neuroleptic-malignant-like response. This bounds the medication landscape and also affects rTMS planning, because some antipsychotics that lower seizure threshold (chlorpromazine, clozapine) would not normally be used in DLB anyway.
DBS overlap
Some patients on the Parkinson's-DLB spectrum have implanted deep brain stimulators in the subthalamic nucleus or globus pallidus internus for motor symptoms. rTMS is contraindicated with implanted DBS per Boston Scientific and Abbott neuromodulation labelling — induced currents can exceed DBS stimulation range and cause over-stimulation or device damage. PEMF over the head should not be used either; PEMF over the body away from the device may be possible with neurologist sign-off.
Visual cortex hyperexcitability
DLB visual hallucinations correlate with occipital-lobe dysfunction. Some pathophysiological models propose hyperexcitability of visual cortex. There is no published evidence that occipital-targeted rTMS is safe in DLB. Any neuromodulation should therefore avoid occipital targets.
REM-sleep behaviour disorder
RBD is highly characteristic of DLB and the Lewy-body spectrum. Standard management is melatonin and clonazepam, with falls-prevention measures (low bed, padded floor). There are no PEMF or rTMS trials specifically for RBD. The dementia-specific sleep section of our pillar covers what limited evidence exists.
The carer angle
DLB has a heavier carer burden than typical Alzheimer's because of fluctuating cognition, hallucinations and falls. The legitimate PEMF use case in a DLB household is for the carer's own stress, sleep and chronic pain — not as a dementia treatment for the person being cared for. See our /insomnia-sleep and /lower-back-pain pages for that evidence.
Frequently asked questions
Has any trial tested rTMS specifically in Lewy body dementia?
As of May 2026, no phase-3 RCT of rTMS specifically in DLB is reported on the public registers. Small case reports exist; they are inadequate for clinical recommendation.
My father has DBS for Parkinson's — can he have rTMS?
No. Implanted deep brain stimulators are an absolute contraindication to rTMS over the head. Induced currents can exceed DBS stimulation range. PEMF over the body away from the implant may be possible with the supervising neurologist's sign-off, but not over the head.
Is the cholinesterase inhibitor my mum is on a problem for PEMF?
Cholinesterase inhibitors (rivastigmine, donepezil) lower seizure threshold modestly. For low-intensity consumer PEMF this is rarely an issue. For clinical rTMS it is a relative consideration that should be reviewed with the prescribing memory clinic.
Can PEMF help with the visual hallucinations?
There is no PEMF or rTMS trial evidence for treating Lewy-body visual hallucinations. Standard management is medication review (especially of dopaminergic and anticholinergic drugs), low-dose quetiapine where appropriate, and environmental modification.
Will PEMF help my dad's REM-sleep behaviour disorder?
There is no published trial. Standard management is melatonin and clonazepam, with falls-prevention measures. Any home PEMF use should not substitute for this.
Are anti-amyloid antibodies relevant in DLB?
Lecanemab and donanemab target amyloid pathology and are licensed in early Alzheimer's. In mixed AD-DLB pathology where amyloid is documented, they may be considered, but the evidence in DLB itself is limited.
Is PEMF safe over the chest in a DLB patient?
If the patient has a pacemaker or ICD it is contraindicated. Otherwise low-intensity PEMF over the body has a benign general safety profile. Falls risk should be assessed when using a floor-mat.
What about magnetic stimulation for the carer?
PEMF has acceptable evidence for chronic pain, stress and sleep — common carer issues. This is wellness use for the carer, not treatment for the person with DLB.
Related dementia pages on PEMF UK
Looking for a PEMF clinic in the UK?
We list every credible PEMF therapy provider in the UK. Please remember: no UK clinic can legally claim to treat dementia with PEMF or rTMS.